Lehmann P V, Cardinaux F, Appella E, Muller S, Falcioni F, Adorini L, Nagy Z A
Preclinical Research, Sandoz Laboratories, Basel, Switzerland.
Eur J Immunol. 1989 Jun;19(6):1071-7. doi: 10.1002/eji.1830190617.
Synthetic peptides corresponding to sequences 46-62 and 51-62 of mouse lysozyme and 46-61 of hen egg-white lysozyme (HEL) were used as competitors in a variety of T cell responses. The competitors, according to their binding specificity for major histocompatibility complex (MHC) were expected to inhibit T cell responses restricted to I-Ak, but not those restricted to I-Ad, I-Ek molecules. In competition experiments with T cell hybridomas, the poor binder I-Ed molecule required 10- to 15-fold higher competitor concentrations than the good binder I-Ak molecule to achieve 50% inhibition of antigen presentation. Similarly, the nonresponder state of H-2d mice to HEL peptide 46-61 could be overcome by increasing the immunizing dose, and proliferative T cell responses to different antigens in association with a variety of class II MHC molecules could be blocked by the mouse lysozyme and HEL peptides. Thus, the capability of some and failure of other MHC molecules to bind certain peptides appeared quantitative, rather than of an all or none nature, in these experimental systems. The susceptibility of uncloned T cell lines to peptide competitors was found to decrease with time. Lines maintained by repeated restimulation with antigen and APC, but without exogenous interleukin 2, acquired resistance within weeks. In contrast, T cell clones retained their susceptibility to peptide competitors over a long period of time. The latter data raise the possibility that a competition between ubiquitous (self) peptides and foreign antigen may result in the selection of T cells that have high avidity for the activating antigen-MHC complex, and are thus relatively resistant to competition at the level of antigen presentation.
与小鼠溶菌酶序列46 - 62和51 - 62以及鸡蛋清溶菌酶(HEL)序列46 - 61相对应的合成肽被用作多种T细胞反应中的竞争者。根据这些竞争者对主要组织相容性复合体(MHC)的结合特异性,预计它们会抑制受I - Ak限制的T细胞反应,但不会抑制受I - Ad、I - Ek分子限制的反应。在与T细胞杂交瘤的竞争实验中,结合能力差的I - Ed分子所需的竞争者浓度比结合能力强的I - Ak分子高10至15倍才能实现50%的抗原呈递抑制。同样,H - 2d小鼠对HEL肽46 - 61的无反应状态可以通过增加免疫剂量来克服,并且与多种II类MHC分子相关的针对不同抗原的增殖性T细胞反应可以被小鼠溶菌酶和HEL肽阻断。因此,在这些实验系统中,某些MHC分子结合特定肽的能力以及其他MHC分子的失败似乎是定量的,而不是全或无的性质。未克隆的T细胞系对肽竞争者的敏感性随时间降低。通过用抗原和抗原呈递细胞反复再刺激维持但无外源性白细胞介素2的细胞系在数周内获得抗性。相反,T细胞克隆在很长一段时间内保持对肽竞争者的敏感性。后一组数据提出了一种可能性,即普遍存在的(自身)肽与外来抗原之间的竞争可能导致选择对活化抗原 - MHC复合体具有高亲和力的T细胞,因此在抗原呈递水平上相对抗竞争。